

This listing of claims will replace all prior versions of claims in the application.

Claims 1-22. (cancelled).

Claim 23. (original) A method for treating an eye comprising:  
inserting into an eye a device comprising a piercing member and a cannula insertable  
within the piercing member, the cannula having a length longer than the length of the piercing  
member.

Claim 24. (original) The method of claim 23 wherein a therapeutic agent is  
administered to a patient's eye through the device.

Claim 25. (original) The method of claim 23 wherein the therapeutic agent is  
administered subretinally to the patient's eye.

Claim 26. (currently amended) The method of claim 23 any one of claims 23  
through 25 wherein the maximum cross-sectional dimension of the portion of the device that  
pierces a patient's eye is about 25 gage or smaller.

Claim 27. (currently amended) A method of treating an eye, comprising:  
inserting a piercing member having an outer diameter into an insertion site, the piercing  
member having a proximal end and a distal end and a lumen defined therebetween;  
advancing a cannula through the piercing member lumen, the cannula having a proximal  
end and a distal end;  
guiding the cannula to a treatment site; and  
treating the treatment site;  
~~withdrawing the cannula from the piercing member; and~~

~~withdrawing the piercing member from the insertion site, wherein the outer diameter of the piercing member is small enough to allow the insertion site to self seal following withdrawal of the piercing member.~~

Claim 28. (original) The method of claim 27 wherein the step of guiding the cannula to the treatment site comprises:

advancing the cannula within the eye until the distal end of the cannula is within the treatment site.

*B)*  
Claim 29. (original) The method of claim 27 or 28 wherein the step of treating the treatment site comprises:

supplying a medicament through the cannula and into the treatment site via the distal end of the cannula.

Claim 30. (currently amended) The method of ~~claim 27 any one of claims 27 through 29~~ wherein the medicament is selected from the group consisting of genes, proteins, cells, small molecule pharmaceuticals and sterile solutions.

Claim 31. (currently amended) The method of ~~claim 27 any one of claims 27 through 30~~ wherein the step of treating the treatment site comprises withdrawing material from the treatment site into the distal end of the cannula.

Claim 32. (currently amended) The method of ~~claim 27 any one of claims 27 through 31~~ wherein the step of inserting the piercing member into the insertion site comprises inserting the distal end of the piercing member into and through the eye's sclera.

Claim 33. (currently amended) The method of claim 27 ~~any one of claims 27 through 32~~ wherein the treatment site is selected from the group consisting of the eye's retina and the eye's vitreous humor.

Claim 34. (currently amended) The method of claim 27 ~~any one of claims 27 through 33~~ wherein the treatment site is the eye's retina and the step of treating the treatment site comprises:

injecting medicament through the cannula and ~~into~~under the retina such that a dome-shaped retinal detachment is formed.

Claim 35. (currently amended) The method of claim 27 ~~any one of claims 27 through 34~~ wherein the outer diameter of the piercing member is about 25 gage or smaller.

Claim 36. (new) The method of claim 23 wherein the device is inserted into the sclera of the eye.

Claim 37. (new) The method of claim 23 wherein the device is advanced transconjunctively through the sclera of the eye.

Claim 38. (new) The method of claim 23 wherein the cannula comprises a polymer.

Claim 39. (new) The method of claim 23 further comprising administering to the eye a therapeutic agent with the device.

Claim 40. (new) The method of claim 39 wherein the therapeutic agent is administered through the cannula to the eye.

Claim 41. (new) The method of claim 39 wherein a steroid is administered to the eye.

Claim 42. (new) The method of claim 39 wherein a therapeutic agent is administered to the eye to treat retinal detachment, vascular occlusion, proliferative retinopathy, diabetic retinopathy, inflammation, degenerative disease, vascular disease or a tumor.

Claim 43. (new) The method of claim 39 wherein the therapeutic agent is administered sub-retinally within the eye.

Claim 44. (new) The method of claim 39 wherein the cannula is positioned within subretinal space of the eye and a therapeutic agent is injected from the cannula into the subretinal space.

Claim 45. (new) The method of claim 23 further comprising removing material from the eye with the device.

Claim 46. (new) The method of claim 45 wherein intravitreal fluid is removed from the eye.

Claim 47. (new) The method of claim 23 wherein the outer diameter of the piercing member is small enough to allow the insertion site to self-seal following withdrawal of the piercing member from the eye.

Claim 48. (new) The method of claim 23 wherein the piercing member outer diameter is about 25 gage or less.

Claim 49. (new) The method of claim 27 wherein the device is inserted into the sclera of the eye.

Claim 50. (new) The method of claim 27 wherein the device advanced transconjunctively through the eye.

Claim 51. (new) The method of claim 27 wherein the cannula comprises a polymer.

Claim 52. (new) The method of claim 27 wherein the treating comprises administering to the eye a therapeutic agent to the eye with the device.

Claim 53. (new) The method of claim 52 wherein a steroid is administered to the eye.

Claim 54. (new) The method of claim 52 wherein a therapeutic agent is administered to the eye to treat retinal detachment, vascular occlusion, proliferative retinopathy, diabetic retinopathy, inflammation, degenerative disease, vascular disease or a tumor.

Claim 55. (new) The method of claim 52 wherein the therapeutic agent is administered sub-retinally in the eye.

Claim 56. (new) The method of claim 27 wherein the treating comprises removing material from the eye with the device.

Claim 57. (new) The method of claim 56 wherein intravitreal fluid is removed from the eye.

Claim 58. (new) The method of claim 52 wherein the cannula is positioned within subretinal space of the eye and a therapeutic agent is injected from the cannula into the subretinal space.

Claim 59. (new) The method of claim 27 wherein the outer diameter of the piercing member is small enough to allow the insertion site to self-seal following withdrawal of the piercing member from the eye.

Claim 60. (new) A method for treating an eye comprising:  
inserting into an eye a device comprising an outer member and a cannula within the outer member within the piercing member, the cannula having a length extending or extendable beyond the outer member distal end.

Claim 61. (new) The method of claim 60 wherein the device is inserted into the sclera of the eye.

Claim 62. (new) The method of claim 60 wherein the device is advanced transconjunctively through the eye.

Claim 63. (new) The method of claim 60 wherein the cannula comprises a polymer.

Claim 64. (new) The method of claim 60 further comprising administering to the eye a therapeutic agent with the device.

Claim 65. (new) The method of claim 64 wherein the therapeutic agent is administered through the cannula to the eye.

Claim 66. (new) The method of claim 64 wherein a steroid is administered to the eye.

Claim 67. (new) The method of claim 64 wherein a therapeutic agent is administered to the eye to treat retinal detachment, vascular occlusion, proliferative retinopathy, diabetic retinopathy, inflammation, degenerative disease, vascular disease or a tumor.

Claim 68. (new) The method of claim 64 wherein the therapeutic agent is administered sub-retinally within the eye.

Claim 69. (new) The method of claim 64 wherein the cannula is positioned within subretinal space of the eye and a therapeutic agent is injected from the cannula into the subretinal space.

Claim 70. (new) The method of claim 60 further comprising removing material from the eye with the device.

Claim 71. (new) The method of claim 70 wherein intravitreal fluid is removed from the eye.

Claim 72. (new) The method of claim 60 wherein the outer diameter of the outer member is small enough to allow the insertion site to self-seal following withdrawal of the piercing member from the eye.

Claim 73. (new) The method of claim 60 wherein the outer member outer diameter is about 25 gage or less.